A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Inclusion Criteria:

Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of

Headache Disorders, 3rd Edition, including the following:

1. Age of onset of migraines prior to 50 years of age

2. Migraine attacks, on average, lasting 4 - 72 hours if untreated

3. Per subject report, at least 15 headache days per month, at lest 8 migraine days permonth, and at least 1 headache-free day per month within the last 3 months prior tothe Screening Visit

4. Eight or more migraine days during the Observation Period

5. 15 or more headache days during the Observation Period

6. One or more non-headache days during the Observation Period

7. Ability to distinguish migraine attacks from tension/cluster headaches

8. Subjects on prophylactic migraine medication are permitted to remain on 1 medicationwith possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the Screening Visit, and the dose is not expected to change duringthe course of the study.

Exclusion Criteria:

1. Subject with a history of HIV disease

2. Subject history with current evidence of uncontrolled, unstable or recentlydiagnosed cardiovascular disease, such as ischemic heart disease, coronary arteryvasospasm, and cerebral ischemia. Subjects with Myocardial Infarction (MI), AcuteCoronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery,stroke or transient ischemic attack (TIA) during the 6 months prior to screening

3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (howeversubjects can be included who have stable hypertension and/or diabetes for at least 3months prior to screening).

4. Subjects with major depressive episode or anxiety disorder which require more than 1daily medication for each disorder or subjects with a major depressive episodewithin the last 12 months. Medications to treat major depressive disorder or ananxiety disorder must have been at a stable dose for at least 3 months prior to theScreening Visit.

5. Subjects with active chronic pain syndromes, other pain syndromes (includingtrigeminal neuralgia), psychiatric conditions, dementia, or significant neurologicaldisorders (other than migraine) that, in the Investigator's opinion interfere withstudy assessments of safety or efficacy.

6. Subject has a history of gastric, or small intestinal surgery (including GastricBypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease orcondition (e.g. chronic pancreatitis, ulcerative colitis, etc.) that causesmalabsorption.

7. Body mass index > 33 kg/m2

8. History of gallstones or cholecystectomy.

9. The subject has a history or current evidence of any unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known or suspectedinfection, hepatitis B or C, or cancer) that, in the investigator's opinion, wouldexpose them to undue risk of a significant adverse event (AE) or interfere withassessments of safety or efficacy during the course of the trial